Viking Therapeutics, Inc. (VKTX)
34.86
+0.88
(+2.60%)
USD |
NASDAQ |
Sep 04, 16:00
34.87
0.00 (0.00%)
After-Hours: 20:00
Viking Therapeutics Cash from Investing (Quarterly) : 109.43M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 109.43M |
| March 31, 2026 | 54.19M |
| December 31, 2025 | 75.61M |
| September 30, 2025 | 160.02M |
| June 30, 2025 | 42.51M |
| March 31, 2025 | 63.24M |
| December 31, 2024 | 6.584M |
| September 30, 2024 | 25.90M |
| June 30, 2024 | -126.06M |
| March 31, 2024 | -459.79M |
| December 31, 2023 | 35.73M |
| September 30, 2023 | -12.53M |
| June 30, 2023 | -204.48M |
| March 31, 2023 | 2.198M |
| December 31, 2022 | 7.26M |
| September 30, 2022 | 26.89M |
| June 30, 2022 | 18.98M |
| March 31, 2022 | 1.619M |
| December 31, 2021 | 27.41M |
| September 30, 2021 | 13.62M |
| June 30, 2021 | 3.56M |
| March 31, 2021 | -6.627M |
| December 31, 2020 | 30.27M |
| September 30, 2020 | -9.634M |
| June 30, 2020 | 9.78M |
| Date | Value |
|---|---|
| March 31, 2020 | 11.15M |
| December 31, 2019 | -11.06M |
| September 30, 2019 | 15.15M |
| June 30, 2019 | 10.98M |
| March 31, 2019 | -7.609M |
| December 31, 2018 | -142.39M |
| September 30, 2018 | -27.09M |
| June 30, 2018 | -66.62M |
| March 31, 2018 | -29.63M |
| December 31, 2017 | -4.396M |
| September 30, 2017 | 1.392M |
| June 30, 2017 | -0.7646M |
| March 31, 2017 | 2.039M |
| December 31, 2016 | 1.447M |
| September 30, 2016 | 0.441M |
| June 30, 2016 | -4.831M |
| March 31, 2016 | 5.973M |
| December 31, 2015 | 1.956M |
| September 30, 2015 | -3.252M |
| June 30, 2015 | -12.17M |
| March 31, 2015 | 0.00 |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | -45.80M |
| Eli Lilly & Co. | -15.40B |
| Regeneron Pharmaceuticals, Inc. | -92.70M |
| Amgen, Inc. | -569.00M |
| Ironwood Pharmaceuticals, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -125.17M |
| Cash from Financing (Quarterly) | 23.59M |
| Free Cash Flow | -418.44M |
| Free Cash Flow Per Share (Quarterly) | -1.077 |
| Free Cash Flow to Equity (Quarterly) | -129.26M |
| Free Cash Flow to Firm (Quarterly) | -125.17M |
| Free Cash Flow Yield | -10.48% |